AUGMENT: lenalidomide plus rituximab versus rituximab alone in relapsed indolent lymphoma
Adding lenalidomide to rituximab more than doubled the time to progression in relapsed follicular and marginal zone lymphoma compared with rituximab alone, establishing a chemotherapy-free option for relapsed indolent lymphoma.
Overview
Phase 3 trial of 358 patients with relapsed or refractory follicular (grade 1 to 3a) or marginal zone lymphoma randomised to lenalidomide plus rituximab (R2) or placebo plus rituximab for 12 cycles.
Median progression-free survival was 39.4 versus 14.1 months (hazard ratio 0.46) and response 78 versus 53 percent; the benefit was clear in follicular lymphoma while the marginal zone subgroup was small and inconclusive. Neutropenia was more frequent with lenalidomide.
- Median progression-free survival 39.4 vs 14.1 months; hazard ratio 0.46.
- Objective response 78 percent vs 53 percent.
Lenalidomide-rituximab is approved for relapsed follicular and marginal zone lymphoma and is a standard chemotherapy-free choice, though marginal zone-specific evidence is thinner.
- Only 63 patients had marginal zone lymphoma, with no clear progression-free survival benefit in that subgroup.
Similar pages
not linked directly; found by shared links- TrialEfficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Shares Marginal zone lymphoma, Lenalidomide, Rituximab.
- TrialA Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Shares Lenalidomide, Rituximab.
- Key paperE3A06: lenalidomide versus observation in smouldering multiple myeloma
Shares Journal of Clinical Oncology, Lenalidomide.
- TrialBrentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Shares Lenalidomide, Rituximab.
- TrialA Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomi
Shares Lenalidomide, Rituximab.
- TrialStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease
Shares Lenalidomide, Rituximab.
- TrialA Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant
Shares Lenalidomide, Rituximab.
- TrialStudy of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Shares Lenalidomide, Rituximab.